Accelerating Diagnosis and Treatment

From the Airway Epithelium to Improved Patient Outcomes

As the treatment armamentarium for severe asthma continues to expand, best practices within its management will continue to evolve, guided by the integration of the latest scientific information, evidence-based recommendations, and an accumulated of real-world clinical experience. This POC¹⁰¹ Microlearning Series™ will be led by two expert faculty who will deliver focused education on the latest developments in biologic therapies for severe asthma that target upstream inflammatory mediators of disease. Utilizing a multimedia format that combines text and video, faculty will discuss the placement of new targeted biologic therapies, treatment selection informed by unique patient and disease profiles, and finally, strategies for monitoring effectiveness and switching.

Multiple sclerosis (MS) is a chronic immune-modulated inflammatory and neurodegenerative disease of the central nervous system. Advances in understanding have led to the development and approval of multiple disease-modifying therapies (DMTs) that offer established safety and efficacy profiles, a variety of mechanisms of action, and different routes of administration to better match an individual patient’s clinical needs, preferences, and tolerance for risk. Issues that have come to the forefront with the approval of more effective therapies include the risk for infection and vaccination requirements as well as optimizing subsequent DMTs when switching is required. When selecting DMTs, it is important to distinguish among multiple therapies in the same class, such as sphingosine-1-phosphate (S1P) receptor modulators, to select the optimal therapy for each patient. Furthermore, novel agents—and classes—are in clinical trials for MS. The rapid pace of advances in this field, however, poses significant challenges to clinicians as they try to keep abreast of evolving awareness of the disease state and strategies for managing patients. The modules in this Phone-a-Friend^TM series will address this need by offering learners the opportunity to hear faculty experts as they engage in data-driven conversations providing practical guidance on a range of key topics in the field of MS, including switching therapies, infection risk, and emerging therapies.

An Immersive Patient and Provider Simulation

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment and Prevention

An Interactive Educational Journey

Target Audience

The educational design of this activity addresses the needs of neurology, psychiatry, and gerontology specialists involved in the treatment of patients with Alzheimer’s disease (AD).

Statement of Need/Program Overview

Alzheimer’s disease (AD) is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. The current understanding of the complex pathophysiology of AD has led to the development of therapies that target amyloid β, tau, and neuroinflammation. Despite its prevalence and significant associated medical, psychosocial, and economic burdens, AD often remains undiagnosed and untreated. As new pathophysiology-linked biomarkers become available and incorporated into practice, diagnosis will improve, thus improving management strategies. However, newer management strategies may result in changes to infrastructure, which will impact each clinician’s practice. In this CME SnapShot series, Dr. Turner and Dr. Cohen will examine AD pathophysiology, optimal strategies to screen patients with suspected mild cognitive impairment (MCI) or AD, the differential diagnoses of MCI and AD, current evidence and regulatory status for newer targeted therapies, ongoing health care disparities in the management of these patients, and potential changes to health care systems as new treatment options become available.

Target Audience

This series of activities is intended for HIV specialists engaged in the care of patients with HIV.

Program Description

As the HIV field continues to advance and patients grow more complex, clinicians often seek out colleagues for advice on certain patients or scenarios. This series of 12 Phone-a-Friend episodes features 2 HIV experts asking and addressing common questions about topics across the landscape of HIV management. The series will cover a variety of topics, including aging patients with comorbidities, mental health, substance use disorder, COVID-19, treatment resistance, implicit bias, and specific patient population, such as transgender patients, women, adolescents, and heavily treatment-experienced patients. Each episode is centered around a specific patient.

New Avenues to the Management of Severe Asthma

Target Audience

This program is intended for primary care providers (PCPs) and other clinicians involved in managing patients with chronic obstructive pulmonary disease.

Reducing LDL-C and a Lifetime of Cardiovascular Risk

A Case-Based Update

A Multimedia eHealth Source™ Educational Initiative

Target Audience

This activity is intended for allergists/clinical immunologists, pulmonologists, pediatricians, and other specialist clinicians involved in the management of pediatric patients with asthma.

Preventing Exacerbations to Improve Outcomes

Debates and Discussions About Monoclonal Antibody Therapies

An Update on Monoclonal Antibody Therapies

Target Audience

The educational design of this activity addresses the needs of primary care clinicians potentially involved in screening, counseling, or treating hepatitis C virus (HCV).

Is Your Practice Up to Date? A Focus on Clinical Evidence and Guideline Recommendations